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Sepsis is a leading cause of death in critical illness, and its pathophysiology varies depending on preexisting medical
conditions. Here we identified nonalcoholic fatty liver disease (NAFLD) as an independent risk factor for sepsis in a large
clinical cohort and showed a link between mortality in NAFLD-associated sepsis and hepatic mitochondrial and energetic
metabolism dysfunction. Using in vivo and in vitro models of liver lipid overload, we discovered a metabolic coordination
between hepatocyte mitochondria and liver macrophages that express triggering receptor expressed on myeloid cells-2
(TREM2). Trem2-deficient macrophages released exosomes that impaired hepatocytic mitochondrial structure and energy
supply because of their high content of miR-106b-5p, which blocks Mitofusin 2 (Mfn2). In a mouse model of NAFLDassociated sepsis, TREM2 deficiency accelerated the initial progression of NAFLD and subsequent susceptibility to sepsis.
Conversely, overexpression of TREM2 in liver macrophages improved hepatic energy supply and sepsis outcome. This study
demonstrates that NAFLD is a risk factor for sepsis, providing a basis for precision treatment, and identifies hepatocytemacrophage metabolic coordination and TREM2 as potential targets for future clinical trials.

Introduction

Sepsis is a lethal syndrome characterized by infection and organ
dysfunction, affecting approximately 19 million individuals per
year worldwide (1). The heterogeneity of septic patients makes
clinical characteristics and disease process extremely variable
(2, 3). Awareness of the precise characteristics and pathogenesis is essential for effective antisepsis treatment. In this context,
improving definition of patient phenotype is needed to allow for
individualized management strategies matched to a patient’s
molecular and biochemical profile. Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in the
world, affecting up to 30% of the adult population (4, 5). NAFLD
encompasses a histological spectrum, ranging from simple steatosis to nonalcoholic steatohepatitis (NASH), the latter of which is
characterized by advanced hepatic inflammation, endoplasmic
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reticulum (ER) stress, mitochondria malfunction, and fibrosis (6).
The established 2-hit model postulates that liver fat buildup makes
hepatocytes vulnerable to second injury (7). Accordingly, NAFLD
is associated with adverse outcomes in many diseases (8–11).
In this study, we initially demonstrated a role of NAFLD in septic mortality in a large clinical cohort, supporting that compromised
hepatic homeostasis is an important component of the maladaptive
host response to sepsis. By investigating the underlying mechanisms, we found that NAFLD is associated with impaired hepatic
mitochondrial homeostasis and energetic metabolism, as well as
the emergence of liver macrophages expressing triggering receptor
expressed on myeloid cells-2 (TREM2). TREM2 is a lipid-binding
cell surface receptor that transmits intracellular signals through the
adapter DAP12. TREM2 has been previously shown to sustain metabolic fitness of microglia during Alzheimer’s disease and to support the ability of adipose tissue macrophages to control metabolic
syndrome in high fat diet (HFD) (12–15). Using in vitro and in vivo
models, we found that liver control of lipid overload involves a metabolic coordination between macrophages and hepatocytes that
depends in part on TREM2. Trem2-deficient macrophages released
exosomes (Exos) that impaired the mitochondria and energy supply
of hepatocytes because of their high content of miR-106b-5p, which
blocks Mfn2. TREM2 deficiency accelerated the progression of
NAFLD and aggravated NAFLD-associated sepsis in vivo, whereas
TREM2 overexpression conversely had a protective effect in these
1
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models. These results demonstrate that NAFLD is a risk factor
for sepsis, providing a basis for precision treatment, and identify
TREM2-dependent hepatocyte-macrophage metabolic coordination as a mechanism that can be targeted to improve NAFLD and
NAFLD-associated pathology, such as sepsis.

Results

NAFLD is an independent risk factor for hospital mortality in critically
ill patients with sepsis. To investigate the contribution of NAFLD to
the mortality of sepsis, we performed a prospective clinical cohort
study. A total of 1307 patients diagnosed with sepsis according
to Sepsis 3.0 criteria were encountered, of which 524 (40.09%)
patients with sepsis who had computed tomography (CT) of the
abdomen within 2 months prior to ICU admission or during ICU
stay were included. The flow diagram of patient enrollment and
exclusion is presented in Figure 1A. The CT diagnosis of hepatic steatosis was made by measuring liver attenuation (LA) in Hounsfield
units (HU). NAFLD was diagnosed when the LA value was ≤ 40
HU (hepatic steatosis area > 30%, moderate-to-severe, Figure 1B,
and refs. 16–19). Of these 524 septic patients, 129 (24.62%) were
identified as NAFLD. The clinical characteristics of 524 adults with
sepsis according to hepatic steatosis categories are summarized in
Supplemental Table 1; supplemental material available online with
this article; https://doi.org/10.1172/JCI135197DS1.
The primary outcomes were 28-day mortality and hospital
mortality after admission to the ICU. Secondary outcomes were
the differences in the need for ventilation, renal replacement therapy (RRT), vasopressor infusions, immunomodulator drugs, and
ICU care according to the hepatic steatosis categories at an interim 28-day time point. Overall, the primary unfavorable outcome
occurred in 104 (28-day mortality, 19.85%) and 121 (hospital mortality, 23.09%) of 524 patients with sepsis.
The NAFLD cohort showed significantly increased 28-day mortality and hospital mortality (32.56% vs. 15.7%, P < 0.0001; 37.21%
vs. 18.48%, P < 0.0001, respectively) compared with the mortality
of the non-NAFLD cohort (Figure 1, C and D). Multivariate logistic
regression was further performed to estimate the effect of NAFLD
on hospital mortality adjusted by age, sex, BMI, and site of infection, and it showed that NAFLD was an independent risk factor
(Figure 1E). The adjusted OR of hospital mortality was 2.92 for the
NAFLD group (95% confidence interval: 1.69–5.03, P < 0.001) (Figure 1E). Interestingly, the 28-day mortality and the hospital mortality of septic patients with NAFLD increased both in patients with
low BMI (28-day mortality: 17.95% vs. 44.12%, P <0.0001; hospital
mortality: 20.77% vs. 51.47%, P < 0.0001) and those with high BMI
(28-day mortality: 9.91% vs. 19.67%, P = 0.0999; hospital mortality: 12.61% vs. 21.31%, P = 0.1877, Supplemental Figure 1, A and B).
Of note, in the low BMI group, the mortality rate of patients with
NAFLD was approximately 2- to 2.5-fold that of patients without
NAFLD (Supplemental Figure 1, A and B). Moreover, in the NAFLD
group, female patients with NAFLD and patients with NAFLD who
were 65 years and older showed higher 28-day and hospital mortality than male patients with NAFLD (28-day mortality: 38.33% vs.
27.54%, P = 0.26; hospital mortality: 46.67% vs. 28.99%, P = 0.046)
and patients with NAFLD who were under age 65 (28-day mortality: 50.0% vs. 19.18%, P = 0.0003; hospital mortality: 50.0 % vs.
27.40%, P = 0.01), respectively (Supplemental Figure 1, C–F).
2

Notably, the Type 2 diabetes comorbidity rate (27.91% vs. 8.1%,
P < 0.001) and plasma glucose value (9.72 ± 4.14 vs. 8.4 ± 3.36,
P = 0.0003) were higher in the NAFLD group compared with the
non-NAFLD group (Supplemental Table 1). Type 2 diabetes has been
demonstrated to increase sepsis mortality risk (20). We repeated the
analysis after excluding these diabetic patients (456 remained). The
28-day mortality (30.11% vs. 15.15%, P = 0.0015) and hospital mortality (35.48% vs. 17.36%, P = 0.0003) were still significantly higher
in the NAFLD group than in the non-NAFLD group (Supplemental
Figure 1G). The same trend was observed in the diabetic patients
(n = 68). The diabetes with NAFLD group had a higher tendency
of 28-day mortality than did the diabetes without NAFLD group
(28-day mortality: 38.89% vs. 21.88%, P = 0.19; hospital mortality:
41.67% vs. 31.25%, P = 0.45, Supplemental Figure 1H). In the NAFLD
group, the 28-day and hospital mortality in patients with and without
diabetes were comparable (28-day mortality: 38.89% vs. 30.11%, P =
0.40; hospital mortality: 41.67% vs. 35.48%, P = 0.55), indicating a
strong link between NAFLD and septic mortality.
Patients with NAFLD had higher SOFA (8.39 ± 4.49 vs. 6.13
± 3.53, P < 0.001) and APACHE II (15.94 ± 6.49 vs. 14.28 ± 5.26,
P = 0.004) scores, and an increased need for immunomodulator drugs (P < 0.001), ventilation (P < 0.001), renal replace treatment (P < 0.001), and ICU days (P < 0.01) compared with patients
without NAFLD (Supplemental Table 1). Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels in patients
with NAFLD were numerically increased (ALT: 185.75 ± 638.95
vs. 103.19 ± 386.38, P = 0.08; and AST: 167.78 ± 756.41 vs. 145.04 ±
456.3, P = 0.07, respectively), although these differences were not
statistically significant (Supplemental Table 1). Together, our results
support that NAFLD is an independent risk factor for septic death.
Patients with NAFLD exhibit liver mitochondria dysfunction. We
next explored the pathology underpinning mortality risk in septic
patients with NAFLD. It has been shown that liver energetic metabolism shifts from glycolysis to long-chain fatty acid oxidation (FAO)
during sepsis to preserve glucose stores for the brain and provide
ATP for the peripheral tissue (21–23). Mitochondria are the primary site for FAO (24). Maladaptation of hepatic mitochondria
has been shown to be a central feature of the transition from simple steatosis to NASH (25, 26). To investigate whether the defects
of energy metabolism and/or mitochondria occurs in NAFLD, we
first performed transcriptome analysis from livers of donors who
underwent organ donation after cardiac death (DCD; 6 non-NAFLD donors, 5 NAFLD donors). In this screen, 462 transcripts were
upregulated and 447 transcripts were downregulated in response
to NAFLD (Figure 2A and Supplemental Data Set 1; GSE160022).
Among these differentially expressed genes (DEGs) (Padj < 0.05),
gene sets that contribute to endoplasmic reticulum stress, intrinsic
apoptosis, and cytokine production were enriched in NAFLD livers.
Conversely, gene sets that contribute to lipid metabolism were suppressed in NAFLD livers, accompanied by deficient expression of
the mitochondrial matrix enzymes (Figure 2, B and C).
Next, we assessed mitochondria damage by examining hepatic
mitochondrial morphology and integrity in an independent NAFLD
cohort (n = 7 in non-NAFLD group, n = 14 in NAFLD group). Hepatocytes in NAFLD samples displayed altered mitochondrial morphology characterized by reduced size and excessive mitochondrial damage compared with non-NAFLD controls, as shown by transmission
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Figure 1. NAFLD is an independent risk factor for hospital mortality in critically ill patients with sepsis. (A) Study flow diagram for identification of septic
patients with or without NAFLD. n = 395 in non-NAFLD group, n = 129 in NAFLD group. (B) Representative CT scan illustrating measurement of patients
with NAFLD or not. (C and D) Kaplan-Meier survival curves (28-day) (C) and hospital mortality (D) across NAFLD category. Significant difference compared
with the non-NAFLD control was determined. n = 395 in non-NAFLD group, n = 129 in NAFLD group. (E) Adjusted hospital mortality according to age, sex,
BMI, and site of infection. The values shown are the adjusted odds ratio (aOR, 95% confidence interval). All sepsis cases: aOR = 2.918 (1.693–5.031, P <
0.001); male: aOR = 2.048 (0.937–4.476, P = 0.072); female: aOR = 4.366 (1.945–9.798, P < 0.001); age <65: aOR = 2.510 (1.163–5.414, P = 0.019); Age ≥65: aOR
= 3.988 (1.766–9.006, P = 0.001); BMI <25: aOR = 3.738 (1.969–7.093, P < 0.001); BMI ≥25: aOR = 1.261 (0.431–3.696, P = 0.672); intra-abdominal: aOR = 3.725
(1.797–7.721, P < 0.001). The data were analyzed by log-rank test (C), or Fisher’s exact test (D), or multivariate logistic regression (E). ****P < 0.0001.

electron microscopy (TEM) (Figure 2, D and E). Consistently, the
NAFLD group (n = 21) exhibited reduced ATP content in the liver and increased ALT and AST levels in the serum compared with
the non-NAFLD group (n = 9, Figure 2F and Supplemental Table 2).
Therefore, our data support that increased mortality risk in septic
patients with NAFLD is associated with hepatic mitochondrial dysfunction, which impairs FAO and energy supply during septic insult.
Livers of patients with NAFLD and a mouse NAFLD model have
abundant TREM2+ macrophages. Tissue-resident macrophages are
the first responding immune cells to organ injury (27, 28). Livers in
human NASH and a mouse model of NASH exhibit a unique subset of macrophages that express triggering receptor expressed in
myeloid cells 2 (TREM2) (29), a lipid receptor that controls metabolism, survival, and proliferation (12, 30). Whether these macrophages are beneficial or detrimental is unknown. Thus, we sought
to examine the livers of patients with or without hepatic steatosis for
changes in macrophage populations. Immunostaining and quantitative polymerase chain reaction (qPCR) analyses showed that the

number of CD68+TREM2+ macrophages and the overall TREM2
expression in the NAFLD donors were significantly increased compared with controls (Figure 3, A and B). The same phenomenon was
also observed in the livers of WT mice fed a HFD (Supplemental
Figure 2A). Next, the monocyte-derived macrophages (MDMs)
and Kupffer cells (KCs) were isolated from WT mice fed HFD for
8 weeks, and qPCR confirmed the high expression of Trem2 in KCs
(Supplemental Figure 2, B and C). It was recently reported that
TREM2+ macrophages in the adipose tissue protect against adipocyte hypertrophy caused by HFD (13). Thus, accumulation of
TREM2+ macrophages in NAFLD may provide a defense mechanism that attenuates liver dysmetabolism occurring in NAFLD.
TREM2 deficiency exacerbates liver mitochondria dysfunction
in a NAFLD mouse model. To investigate whether TREM2 has a
protective role against metabolic dysfunction in a mouse model
of NAFLD, 8-week-old Trem2-deficient (Trem2–/–) and littermate
WT mice were fed a normal chow diet (NCD) or a HFD for 8 weeks
and their livers were excised and evaluated (Figure 4A). Upon
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Figure 2. NAFLD patients exhibit liver mitochondria dysfunction. (A) Volcano plot showing significant DEGs (red, downregulated genes; blue, upregulated genes, Padj < 0.05) in NAFLD versus non-NAFLD livers. n = 6 in non-NAFLD group; n =5 in NAFLD group. (B) GO analysis of the identified DEGs between
non-NAFLD and NAFLD livers. Orange (top panel) and blue (bottom panel) indicate downregulated and upregulated GO biological processes or cellular
component in NAFLD livers, respectively. (C) Heatmap showing the expression pattern of the identified DEGs that were found to be involved in fatty acid
metabolism, mitochondrial matrix, endoplasmic reticulum stress, apoptosis, and inflammation. The color key indicates the expression levels. (D) Representative images of H&E-stained and ORO-stained liver sections and TEM images from non-NAFLD and NAFLD livers. H&E-stained and ORO-stained liver
sections: n = 9 in non-NAFLD group; n = 21 in NAFLD group. TEM images: n = 7 in non-NAFLD group; n = 14 in NAFLD group. Solid and dashed white arrows
refer to complete and fragmented mitochondria, respectively. Scale bars: 50 μm, 10 μm, and 2 μm. (E) Quantification of mitochondrial parameters from liver electron microscopy images from NAFLD and non-NAFLD patients. n = 601 mitochondria from 14 NAFLD patients or 238 mitochondria from 7 controls (3
fields/patient). (F) ATP levels in livers from non-NAFLD and NAFLD patients. n = 9 for non-NAFLD patients; n = 21 for NAFLD patients. All data are shown
as the mean ± SD. Significance was determined by an unpaired, 2-tailed Student’s t test. ****P < 0.0001.
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Figure 3. TREM2+ macrophages are characteristic of livers from NAFLD
patients. (A) Confocal images of liver sections from non-NAFLD and
NAFLD donors show CD68 (cyan), TREM2 (red) and DAPI staining. Individual CD68+ TREM2+ macrophages are depicted at a higher magnification in
the inserts. Confocal images at ×40 were taken with a Nikon A1 inverted
fluorescent microscope. n = 6 in non-NAFLD group; n = 7 in NAFLD group.
Scale bar: 20 μm. (B) qPCR analysis for liver TREM2 expression normalized
to β-actin mRNA levels. n = 9 in non-NAFLD group; n = 21 in NAFLD group.
All data are shown as the mean ± SD. Significance was determined by an
unpaired, 2-tailed Student’s t test. **P < 0.01.

HFD feeding, Trem2–/– mice gained more body weight, epididymal fat pad weight, liver weight, and liver weight–to–body weight
ratios (Figure 4, B and C; Supplemental Figure 3, A and B). Trem2
deletion increased serum and liver triglyceride (TG) by 30%, as
well as serum and liver cholesterol by 20% and 15%, respectively
(Figure 4, D and E). H&E and Oil Red O (ORO) staining showed
that Trem2–/– livers exhibited increased macrovesicular fat content,
aggravated lipid droplet (LD) accumulation, and ballooning degeneration (Figure 4F). In contrast, there was no difference between
WT and Trem2–/– mice fed a NCD (Supplemental Figure 3, C–G).
We performed unbiased transcriptome analysis of livers of WT
versus Trem2–/– mice after feeding mice a HFD for 8 weeks (31). In
this screen, a cluster of 104 transcripts were upregulated and 57
were downregulated in response to Trem2 deficiency (Supplemental Data Set 2 and Supplemental Figure 4A; GSE160022). Among
these DEGs (Padj < 0.05), gene sets that contribute to fatty acid
metabolic dysfunction, collagen fibril organization, and cytokine
secretion were significantly enriched in Trem2–/– livers, whereas
those controlling long-chain/unsaturated fatty acid metabolism
and monocarboxylic acid metabolism were overrepresented in
WT livers (Figure 4, G and H). qPCR analysis in an independent
cohort further confirmed that livers of HFD-fed Trem2–/– mice
had reduced expression of genes involved in the metabolic fates

of polyunsaturated fatty acids (PUFAs), including long-chain
fatty-acid CoA ligase 4 (Acsl4), steroid hormone metabolism
(Hsd3b5), and hepatic trefoil factor 3 (Tff3). The expression of
lipogenesis genes (Apoa4, CD36, and Cidea) and inflammatory
cytokine genes (Ccl2, Ly6d, Cxcl10, and TNF-α) were upregulated
in Trem2–/– livers (Supplemental Figure 4B). These data indicate
that Trem2 deficiency exacerbates the progression of NAFLD.
Last, we asked whether a defect of TREM2 impacted liver
energetic metabolism and mitochondria function. Tandem mass
spectrometry was first used to detect metabolites in both positive
and negative ion modes in the livers of WT and Trem2–/– mice fed
HFD for 8 weeks, after an overnight fasting. Totally, 219 and 201
lipids and lipid-like molecules were identified in the positive and
negative ion modes, respectively (Supplemental Data Set 3). The
levels of major fatty acid species, including ricinoleic acid (RA),
linoleic acid (LA), dodecanedioic acid (DA), and arachidonic acid
(AA), were more elevated in Trem2–/– versus WT livers (Figure 4I
and Supplemental Figure 4C, P < 0.05). Acylcarnitine (AC) species
ranging in size from 2 to 22 carbons were also analyzed, representing byproducts of substrate catabolism. Ions separating Trem2–/–
and WT livers were identified as long-chain AC species (ranging
from C14:0 to C22:0; Figure 4I, P < 0.05), suggesting insufficient
l-carnitine shuttle of long-chain fatty acids from the cytosol to
the mitochondria in Trem2–/– liver. In support of this, hepatic mitochondria in Trem2–/– mice were less uniform and more fragmented compared with those in WT mice (Figure 4J). Moreover, mice
lacking Trem2 exhibited reduced ATP levels in the liver (Figure
4K). Together, these results suggested that Trem2–/– liver is unable
to appropriately adjust FAO and energy metabolism due to mitochondrial fragmentation after HFD.
TREM2 promotes macrophage-hepatocyte metabolic coordination both in vivo and in vitro. To explore whether the aggravation
of hepatic steatosis in HFD-fed Trem2–/– mice is due to a defect of
liver KCs, we depleted the KCs of HFD-fed WT and Trem2–/– mice
by administration of gadolinium chloride (GdCl3, Figure 5A, and
ref. 32). Depletion of KCs was confirmed by a greater than 40%
decrease in F4/80+ cells and the approximately 50% decrease in
F4/80 mRNA expression in the liver (Supplemental Figure 5, A and
B). Overall, compared with control mice, mice with KC depletion
gained less body weight and had improved lipid metabolism, as
evidenced by a decrease of serum and hepatic TG and cholesterol
contents after 8 weeks of HFD (Figure 5, B and C, and Supplemental Figure 5C). Interestingly, in the GdCl3 group, Trem2–/– and WT
mice showed comparable liver and serum TG and cholesterol contents, liver fat accumulation, and ATP production (Figure 5, B–E).
Together, these data support that Trem2–/– liver KCs aggravate the
development of hepatic steatosis.
To further define the beneficial roles of TREM2 in hepatic
steatosis in vitro, bone marrow–derived macrophages (BMDMs)
from WT or Trem2–/– mice were cocultured with primary hepatocytes isolated from WT or Trem2–/– mice in trans-well plates (Figure 5F). Cultures were supplemented with palmitic acid (PA, 0.5
mM) for 24 hours in serum-free conditions. A drastic increase
in LDs was observed in both WT and Trem2–/– hepatocytes when
cocultured with Trem2–/– macrophages (Figure 5G). Under these
conditions, a luciferase-based ATP assay showed that ATP
production decreased in hepatocytes cocultured with Trem2–/–
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Figure 4. Trem2 deficiency exacerbates hepatocyte mitochondrial dysfunction and accelerates NAFLD progression in a mouse model. (A) Experimental
design used to evaluate the role of Trem2 in NAFLD progression. Liver weights
(B) and liver weight/body weight ratios (C) of WT and Trem2–/– mice after being
fed HFD for 8 weeks. n = 10 in WT group; n = 13 in Trem2–/– group. Levels of
TG (D) and cholesterol (E) in serum and livers from mice after being fed HFD
for 8 weeks. n = 6 in WT group; n = 9 in Trem2–/– group. (F) Representative
images of H&E- and ORO-stained liver sections. n = 4 in WT group; n = 4-5
in Trem2–/– group. Solid and dashed black arrows indicate hepatocytes with
macrovesicular fat (Macroves. fat) or hepatocyte ballooning (Hep. balloon.),
respectively. Number of hepatocytes with Macroves. fat or Hep. balloon. and
percentage of ORO-positive area per high magnification field (HMF) was determined by ImageJ from 6 fields per section. Scale bar: 100 μm. (G) GO analysis
of the identified DEGs between WT and Trem2–/– groups (n = 3 per group). (H)
Heatmap showing the expression pattern of the identified DEGs (n = 3 per
group). The color key indicates the expression levels. (I) Heatmap displays the
upregulated and downregulated lipid species in livers (n = 9 mice per group), P
< 0.05. The color key indicates the lipid levels. (J) Representative TEM images
of mouse hepatocytes (upper) and hepatocellular mitochondria (bottom). n =
4 in WT group; n = 5 in Trem2–/– group. Solid and dashed white arrows refer to
complete and fragmented mitochondria, respectively. Scale bars: 10 μm and 1
μm, respectively. (K) ATP levels in WT and Trem2–/– livers. n = 7 per group. All
data are shown as the mean ± SD. The data were analyzed by an unpaired,
2-tailed Student’s t test. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.

macrophages compared with the hepatocytes cocultured with WT
BMDMs (Figure 5H). These results support that TREM2 deficiency impairs macrophage-hepatocyte metabolic coordination in a
fatty acid–enriched microenvironment.
Trem2 deletion leads to changes in macrophage-Exos numbers
and content. To explore the potential mechanism underlying FAO
defects in livers from Trem2–/– mice fed HFD for 8 weeks, we profiled KC transcriptomes isolated from these mice and their WT
littermates by RNA-seq (Supplemental Data Set 4; GSE160022).
Gene ontology (GO) analysis revealed that antigen processing and
presentation, mitochondrial oxidative phosphorylation, and ATP
synthesis were impaired in Trem2–/– KCs. However, genes linked
to chemotaxis and inflammation (Ccr2, Cx3cr1, Spp1) were upregulated in Trem2–/– KCs (Figure 6A and Supplemental Figure 6A).
Interestingly, genes involved in Exos secretion (Cd63, Cd9) were
enriched in Trem2–/– KCs (Supplemental Figure 6A).
Macrophage-derived Exos can be taken up into hepatocytes to
modulate the function of recipient cells (33). Thus, we conducted
in vitro studies to confirm whether Trem2–/– macrophage-derived
Exos were the underlying mechanism of Trem2–/– liver FAO defects
and ATP deficiency. BMDMs with different genotypes were stimulated with PA (0.5 mM) or control vehicle for 12 hours. After
removal of dead cells and debris from the conditioned medium,
extracellular vesicles (EVs) were isolated by differential ultracentrifugation. These EVs were confirmed to primarily consist of Exos,
as evidenced by the expression of the Exos-specific protein markers CD63, CD81, and Alix, but not cytochrome C (mitochondria),
GM-130 (Golgi), or calnexin (ER) proteins (Supplemental Figure
6B). TEM (Figure 6B) and NanoSight analysis (Figure 6C) corroborated that the particles were BMDM-derived Exos (BMDM-Exos)
with a diameter of 30–150 nm. The overall Exos number isolated
from the same amount of medium from the Trem2–/– BMDMs group
was much higher than that from WT BMDMs group (Figure 6C).
Next, we incubated the WT primary hepatocytes with equal
amounts of WT or Trem2–/– BMDM-Exos (20 μg/mL) for 12 hours

under PA (0.5 mM) stimulation. Compared with WT BMDM-Exos–
treated hepatocytes, hepatocytes incubated with Trem2–/– BMDMExos showed a significant increase in LD accumulation (Figure 6D),
suggesting that the composition of WT BMDM-Exos and Trem2–/–
BMDM-Exos diverges under a fatty acid–rich environment. Further,
to replicate the in vitro phenomenon in vivo, WT mice fed a HFD
for 7 weeks were used as recipients and intravenously injected with
PKH26-labeled WT or Trem2–/– BMDM-Exos for 3 weeks (30 μg
every 7 days, Figure 6E). The appearance of red fluorescent PKH26
dye in the livers of recipient mice indicated the in vivo uptake of
Exos in the liver (Supplemental Figure 6C). Compared with the WT
BMDM-Exos group, Trem2–/– BMDM-Exos–injected mice gained
more liver weight and liver weight–to–body weight ratios, while
the body weight and epididymal fat pad weights were comparable between the 2 groups (Figure 6F and Supplemental Figure 6,
D and E). Trem2–/– BMDM-Exos–injected mice showed increased
serum and liver TG content and hepatic LD accumulation (Figure
6, G–I). ATP production was lower in the livers of Trem2–/– BMDMExos–injected mice compared with WT BMDM-Exos–injected mice
(Figure 6J). Therefore, our data show that liver macrophage TREM2
attenuates NAFLD progression in an Exos-dependent manner.
Macrophage-derived Exos impair hepatocyte mitochondria due to
high content of miR-106b-5p that blocks Mfn2. miRNAs are regulatory molecules that can be packaged into Exos and secreted from
cells (33–35). To assess the NAFLD-induced changes in expression of KCs miRNAs, we conducted deep sequencing of small
RNAs from KCs isolated from WT and Trem2–/– mice fed HFD for
8 weeks. More than 1000 miRNAs were identified in KCs (Supplemental Data Set 5; GSE160022). A set of miRNAs were upregulated in Trem2–/– versus WT KCs, among which miR-106b-5p was
the most abundant miRNA in KCs (Figure 7A, Supplemental Data
Set 5, and ref. 36). In an independent cohort, our results confirmed
that KCs from Trem2–/– mice expressed greater intracellular levels
of miR-106b-5p after 8 weeks of HFD feeding (Supplemental Figure 7A), which led to increased levels of miR-106b-5p present in
the livers (Supplemental Figure 7B). Consistent with these in vivo
results, the miR-106b-5p abundance was significantly increased in
Trem2–/– BMDM-Exos (~6-fold) after treatment with PA (0.5 mM)
for 12 hours (Supplemental Figure 7C).
To evaluate the role of miR-106b-5p on lipid metabolism, we
transfected BMDMs with Cy3-labeled miR-106b-5p mimic or
negative control (NC) via lipofectamine RNAiMAX (Supplemental Figure 7, D and E). After 12 hours of coculture with miR-106b5p mimic–transfected BMDMs, the hepatocyte exhibited efficient
uptake of the macrophage-secreted miR-106b-5p (~80% efficiency), as indicated by the presence of red fluorescence (Supplemental Figure 7D) and increased miR-106b-5p abundance within the
hepatocytes (Supplemental Figure 7F). The increased miR-106b5p abundance in hepatocytes led to a significant increase in LD
accumulation after PA treatment for 12 hours in serum-free conditions, accompanied by decreased ATP production within the
hepatocytes (Figure 7, B and C).
miR-106b-5p was previously reported to target Mfn2 (37). Mfn2
plays a crucial role in controlling mitochondrial fusion, which is
required for oxidative phosphorylation, mitochondrial DNA biogenesis, mitophagy regulation, and metabolic adaptation (38).
Since Mfn2 ablation in the liver was shown to cause a NASH-like
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Figure 5. Macrophage Trem2 deficiency exacerbates hepatocyte lipid accumulation both in vivo and in vitro. (A) Schematic representation of the timing
strategy used to evaluate the role of KCs in NAFLD progression. n = 12 in WT CTRL group; n =5 in Trem2–/– CTRL group; n =10 in WT GdCl3 group; n =5 in
Trem2–/– GdCl3 group. (B and C) Serum and liver triglyceride or cholesterol levels in response to KCs depletion. (D) Representative images of H&E- and OROstained liver sections. H&E reveals tissue composition and macrovesicular fat, and ORO visualizes lipid droplets. Number of hepatocytes with macrovesicular fat and percentage of ORO-positive area per HMF was determined by ImageJ from 6 fields per section. Scale bar: 100 μm. (E) ATP contents in the
liver. (F and G) Representative image of ORO-stained hepatocytes after coculture with BMDMs (F). BMDMs from WT or Trem2–/– mice were cocultured with
primary hepatocytes isolated from WT or Trem2–/– mice in transwell plates. Cultures were added with PA (0.5 mM) for 24 hours in serum-free conditions.
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Lipid accumulation in hepatocytes was determined by quantification of
ORO-positive area as a percentage of whole image area by ImageJ (G). n = 9
per group. Scale bar: 50 μm. (H) ATP content in hepatocytes was quantified by luciferase assay. n = 9 per group. The data were analyzed by 1-way
analysis of variance with Bonferroni corrections for multiple comparisons.
All data are shown as the mean ± SD. *P < 0.05, **P < 0.01, ***P < 0.001,
****P < 0.0001.

phenotype and liver cancer (39, 40), we examined whether the
upregulated miR-106b-5p downregulates Mfn2 protein levels and
causes mitochondrial dysfunction in our model. BNL.CL2 hepatocytes were transfected with the indicated miR-106b-5p mimic
or NC and examined by immunoblotting. As shown in Figure 7D,
overexpression of miR-106b-5p markedly downregulated Mfn2
protein levels in hepatocytes. Taken together, Trem2–/– macrophages
exacerbate hepatocyte FAO dysfunction by promoting macrophage
release of Exos that impair hepatocyte mitochondrial homeostasis
through their content of miR-106b-5p, which blocks Mfn2.
Trem2 deficiency increases the susceptibility to NAFLD-associated
sepsis in vivo. To further assess the involvement of TREM2 in the
susceptibility of NAFLD mice to sepsis, we performed a survival
study on WT and Trem2–/– mice fed a NCD or HFD for 8 weeks.
After dietary intervention, lethal polymicrobial sepsis was induced
by cecal ligation and puncture (CLP), and mice were monitored
for 3-day survival (Figure 8A). We found that all of the HFD-fed
mice (WT and Trem2–/–) died within 3 days following the surgery,
whereas less than 40% of NCD-fed mice (WT and Trem2–/–) died
within the 3-day study period (Figure 8B). Compared with WT
NAFLD mice, Trem2–/– NAFLD mice had a shorter survival time
following induction of lethal sepsis (Figure 8B).
To explore the factors that exacerbate septic mortality, systemic bacterial burden and cytokines were measured. Compared with HFD-fed WT mice, the systemic bacteria burden was
increased in HFD-fed Trem2–/– mice after sepsis insult; however,
there was no difference between the NCD-fed Trem2–/– mice and
HFD-fed Trem2–/– mice (Figure 8C). Additionally, there was no significant difference in cytokine production among different mouse
genotypes either with NCD or HFD treatment (Figure 8D). Given
the difference in the survival between the HFD-fed Trem2–/– group
and the other 3 groups, our data suggested that factors other than
bacterial burden and proinflammatory cytokines worsen the sepsis outcome in HFD-fed Trem2–/– mice.
Furthermore, TEM showed more severe mitochondrial fragmentation in Trem2–/– livers than in WT livers, accompanied by a
significant decrease in ATP production (Figure 8, E and F), indicating that the fragility of HFD Trem2–/– liver may be an important risk factor in sepsis insult. In support of this possibility, more
severe liver injury and lung injury were observed in Trem2–/– than
that in WT mice on day 1 after CLP insult, as evaluated by bleeding
and inflammatory cell infiltration (Supplemental Figure 8A). The
plasma ALT concentration of HFD-fed Trem2–/– mice was approximately double that in HFD-fed WT mice (Supplemental Figure
8B). In addition, there was about 50% decrease in plasma albumin
concentration in the HFD-fed Trem2–/– mice (Supplemental Figure
8C), indicating that liver failure occurred in HFD-fed Trem2–/–mice.
An additional LPS-induced sepsis model (10 mg/kg LPS) was
performed in NCD-fed Trem2–/– and WT littermates. NCD-fed

Trem2–/– mice showed comparable survival and organ injury to the
NCD-fed WT mice (Supplemental Figure 8, D–F), corroborating that
TREM2 deficiency increases the susceptibility to septic insult only
in the presence of a liver metabolic disorder caused by HFD. Taken
together, our results support the notion that liver metabolic failure
and severe liver dysfunction are important causes of septic death in
HFD-fed Trem2–/– mice. We do not exclude that defects in the Trem2–/–
macrophages of other organs may also contribute to septic death.
Elevated TREM2 gene dosage in liver macrophages suppresses steatohepatitis and relieves sepsis-induced organ dysfunction. To
further corroborate that macrophage TREM2 alleviates altered
hepatic energetic metabolism and subsequent liver dysfunction
in NAFLD-associated sepsis, we tested whether increasing the
macrophage TREM2 gene dosage could modify disease pathogenesis. We generated a transgenic mouse line expressing the
common variant of human TREM2 (BAC-TREM2) in addition to
WT endogenous TREM2. Because human and mouse TREM2 are
highly homologous and have evolutionarily conserved functions,
BAC-TREM2 mice provide a model of TREM2 overexpression (41,
42). BAC-TREM2 and WT littermates were placed on HFD for 10
weeks (Figure 9A). To verify cell type–specific expression of human
TREM2 transgene in livers of mice fed HFD for 10 weeks, we performed immunofluorescence microscopy of liver sections using
an antibody against the C terminus of human TREM2. Human
TREM2 colocalized exclusively with the macrophage marker
Iba1 (Supplemental Figure 9A). In parallel, real-time qPCR data
showed BAC-TREM2 mice expressed murine Trem2 transcripts at
levels comparable to WT mice after 10 weeks of HFD (Supplemental Figure 9B). Upon HFD feeding, BAC-TREM2 mice featured
decelerated body/liver weight gain (Figure 9, B and C and Supplemental Figure 9C). No difference was detected in white adipose
tissue weight between the BAC-TREM2 mice and WT littermates
(Supplemental Figure 9D). H&E and ORO analysis of liver sections showed that BAC-TREM2 mice had alleviated macrovesicular fat content, ballooning degeneration and lobular inflammation, and less LD accumulation after 10 weeks of HFD (Figure 9,
D–F). Consistently, BAC-TREM2 mice showed improved hepatic
FAO after overnight fasting, as evidenced by decreased hepatic
TG content and increased ATP production (Figure 9, G and H).
To determine whether the elevated macrophage TREM2 dosage could impact susceptibility of NAFLD mice to polymicrobial
sepsis-induced liver injury, sepsis was induced by mild CLP and
mice were monitored for organ injuries, systemic bacteria burden,
and cytokine production. Liver injury and lung injury were alleviated in the BAC-TREM2 group compared with WT littermates,
accompanied by low blood bacteria burden and improved hepatic
ATP production (Figure 9, I–K). There was no difference in systemic cytokine production, except for a trend in MCP-1 reduction
in the BAC-TREM2 group (Supplemental Figure 9E). Overall, our
data suggest that TREM2 overexpression in liver macrophages
plays a protective role in defense against NAFLD-associated sepsis by facilitating liver switch to FAO metabolism.

Discussion

The liver is a prime target in sepsis-related injury, especially in the
context of preexisting hepatic impairment (43). Here, we performed
a clinical cohort study and showed that NAFLD is an independent
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Figure 6. Trem2 deletion changes macrophage-Exos numbers and contents. (A) GO analysis of DEGs in KCs from WT or Trem2–/– mice fed HFD for 8 weeks.
n = 3 per group. (B) Representative TEM images of Exos from WT and Trem2–/– BMDMs incubated with PA (0.5 mM) for 12 hours. Scale bar: 100 nm. (C)
Representative results of nanoparticle tracking analysis demonstrate size distribution of Exos derived from WT and Trem2–/– BMDMs. n = 5 per group. (D)
WT primary hepatocytes were incubated with WT or Trem2–/– BMDM-derived Exos (20 μg/mL) and PA (0.5 mM) for 12 hours. Lipid accumulation in hepatocytes was determined by quantification of ORO-positive area as a percentage of whole image area by ImageJ. n = 16 in WT group; n = 19 in Trem2–/– group.
Scale bar: 25 μm. (E) Experimental design used to evaluate BMDM-Exos in NAFLD progression. n = 6 in WT-Exos group; n = 5 in Trem2–/–-Exos group. (F)
Liver weights and liver weight/body weight ratios of mice with Exos treatment. (G and H) Serum and liver triglyceride levels in response to Exos treatment. (I) Representative images of ORO-stained liver sections from mice treated with Exos from WT or Trem2–/– BMDMs. Scale bar: 100 μm. Percentage of
ORO-positive area per HMF were determined by ImageJ from 6 fields per section. (J) ATP content in hepatocytes was quantified by luciferase assay. Data
are presented as the mean ± SD. The data were analyzed by an unpaired, 2-tailed Student’s t test. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.
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Figure 7. Trem2 deletion impacts macrophage-Exos miRNA profiles. (A)
Heatmap of small RNA transcripts in WT and Trem2–/– KCs after 8-week
HFD and sequence alignment of miR-106b-5p with 3′ UTRs of mouse
(Mmu), human (Hsa), and rat (Rno) Mfn2. n = 4 for each group. The color
key indicates the expression levels. (B and C) WT BMDMs were transfected
with either NC or miR-106b-5p mimic and then cocultured with primary WT
hepatocytes in a transwell plate for 12 hours with 0.5 mM PA stimulation.
Lipid accumulation in hepatocytes was determined by quantification of
ORO-positive area as a percentage of whole image area by ImageJ (B), n =
9 per group. Scale bar: 25 μm. ATP content in hepatocytes was quantified
by luciferase assay (C), n = 6 per group. (D) Representative Western blot
images of Mfn2 expression in BNL CL.2 cells, which were transfected with
either NC or miR-106b-5p mimic and then stimulated with 0.5 mM PA for
6 hours. The integrated density of the blots was analyzed by ImageJ. n = 3
per group. Data are presented as the mean ± SD. Data were analyzed by an
unpaired, 2-tailed Student’s t test. *P < 0.05, ****P < 0.0001.

risk factor for hospital mortality after adjusting for age, sex, BMI,
and site of infection. Liver transcriptome analysis and liver biopsies
showed that mortality in NAFLD-associated sepsis was associated with impaired lipid metabolism, severe hepatic mitochondrial
fragmentation, and decreased ATP content. Remarkably, we found

that NAFLD was paralleled by the expansion of liver macrophages
expressing TREM2, which impacted hepatic mitochondrial dysfunction. Trem2-deficient macrophages released Exos that impaired
hepatocytic mitochondrial structure and energy supply because of
their high content of miR-106b-5p, which blocks Mfn2. Trem2 deletion exacerbated NAFLD as well as susceptibility of mice to sepsis.
Conversely, overexpression of TREM2 in liver macrophages attenuated steatohepatitis and sepsis-induced mortality. Collectively,
these findings support hepatic mitochondrial dysfunction as a significant mediator of the pathogenesis of NAFLD and NAFLD-associated sepsis, and demonstrate a role for macrophage TREM2 in protecting hepatocytes against mitochondrial dysfunction (Figure 10).
Frequently, septic patients exhibit chronic diseases such as
NAFLD, which is the most common chronic liver disease (4, 5). In
our current prospective clinical cohort study, 24.62% patients with
sepsis were identified as NAFLD. The NAFLD cohort showed significantly increased 28-day mortality and hospital mortality compared with the non-NAFLD cohort. Moreover, within the NAFLD
cohort, female patients and patients aged 65 and over had a predominantly higher risk for adverse clinical outcomes following sepsis than patients in the other cohorts, probably due to the high rate
of comorbidities in those patients. Diabetes is known to strongly
associate with NAFLD, but whether this may lead to adverse clinical outcomes was unknown (20). We found that both the 28-day
mortality and hospital mortality in the NAFLD group were still significantly higher than the non-NAFLD group after excluding these
diabetic patients. The same tendency was also observed in diabetic
patients. Moreover, in the NAFLD group, the mortality in patients
with and without diabetes was comparable, indicating a strong
link between NAFLD and septic mortality. Since sepsis is associated with a shift from glycolysis to FAO for energy supply in the
liver (22), lipid overload and excess of toxic fatty acids in NAFLD
may impair mitochondrial FAO, affecting liver function and, consequently, energy supply to other vital organs during sepsis. Thus,
targeting hepatic FAO and energy metabolism may improve the
outcome of septic patients with NAFLD.
A recent study identified the emergence of Trem2+ NASHassociated KCs as a feature of mouse and human NASH (29). In
our study, liver immunostaining also revealed increased numbers
of CD68+TREM2+ and F4/80+TREM2+ KCs in NAFLD donors and
HFD-fed mice, respectively. Since it was shown that monocytes can
acquire a KC profile once they reach the space of Disse (44), whether TREM2+ KCs in NAFLD livers are bona fide KCs or derive from
the infiltration and differentiation of monocytes remains unclear.
TREM2 was recently shown to control lipid metabolism in microglia and adipose tissue macrophages (12, 13, 30). Our study extends
these findings, showing that deletion of Trem2 in a mouse NAFLD
model increased hepatocyte lipid content and accumulation of fatty
acid species, reduced long-chain acylcarnitine species and ATP production, and augmented mitochondria fragmentation. Moreover,
Trem2–/– NAFLD mice showed worse outcomes than WT NAFLD
mice following polymicrobial sepsis, whereas overexpression of
TREM2 on KCs alleviated NAFLD and adverse septic outcome.
While the impact of TREM2 on sepsis outcome may be due to its
influence on hepatocyte energy supply, FAO, and mitochondrial
function, we cannot exclude additional contributions of TREM2 to
other macrophage compartments involved in immune responses.
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Figure 8. Trem2 deficiency increases susceptibility to NAFLD-associated sepsis. (A) Experimental design used to set up NAFLD and sepsis. (B) WT and
Trem2–/– mice fed NCD or HFD for 8 weeks were subjected to lethal CLP with an 18-gauge needle, and mice survival was monitored every 12 hours. n = 10 for
NCD WT mice; n = 11 for NCD Trem2–/– mice; n = 11 for HFD WT mice; n = 13 for HFD Trem2–/– mice. (C) Blood bacterial burden at 24 hours post-CLP. n = 5 for NCD
WT mice; n = 6 for NCD Trem2–/– mice; n = 4 for HFD WT mice; n = 6 for HFD Trem2–/– mice. (D) Plasma cytokine markers were quantified 24 hours after CLP.
n = 5 per group. (E) Representative TEM images of mouse hepatocellular mitochondria obtained from WT or Trem2–/– mice livers 24 hours after CLP. n = 2–6 for
each group. Scale bar: 1 μm. (F) Levels of ATP contents in livers from WT or Trem2–/– mice at 24 hours after CLP. n = 7 in WT NCD group; n = 8 in Trem2–/– NCD
group; n = 6 in WT HFD group; n = 9 in Trem2–/– HFD group. Data are presented as the mean ± SD. Data were analyzed by 1-way analysis of variance with Bonferroni corrections for multiple comparisons (C, D, and F). The survival rates were analyzed by log-rank test (B). *P < 0.05, **P < 0.01, ***P < 0.001.

The critical role of macrophage TREM2 in attenuating lipid
accumulation in hepatocytes in the NAFLD model was corroborated by an in vivo KC depletion model and in vitro coculture system.
Since TREM2 is expressed in macrophages but not hepatocytes,
how could TREM2 in liver KCs control lipid metabolism in hepatocytes? We found that the role of macrophage TREM2 in hepatic lipid
handling and catabolism was related to the Exos pathway: Trem2–/–
macrophages released more Exos than WT macrophages, and Exos
were taken up by neighboring hepatocytes modulating their function through miRNAs (33). Among several miRNAs, we focused on
miR-106b-5p because it was enriched in KCs, was upregulated in
obese adipose tissue macrophage–derived Exos (33, 36), and was
shown to target the mitochondrial membrane protein Mfn2, which
is important for mitochondria function (37, 39). In a transwell assay,
Cy3-labeled miR-106b-5p transfected in macrophages was readily
detected in hepatocytes with hundreds of fold increase in expression. This increase in hepatocyte abundance of miR-106b-5p led to
a significant increase in lipid droplet accumulation after PA treatment, accompanied by decreased ATP production and Mfn2 downregulation. Understanding how TREM2 controls Exos secretion and
miR-106b-5p expression will require additional studies.
12

In conclusion, by examining a large cohort of patients with
NAFLD and sepsis, we defined the contribution of NAFLD to sepsis
mortality. Our findings underscore the importance of mitochondrial metabolic dysfunction in the pathogenesis of NAFLD-associated sepsis, show that metabolic coordination between liver macrophages and hepatocytes protects from NAFLD, demonstrate the
requirement for TREM2 for such coordination, and highlight the
TREM2 pathway as a potential avenue of therapeutic intervention
for NAFLD-associated sepsis.

Methods

Study design, setting, and population. Patients who met the Sepsis 3.0
clinical criteria were screened for eligibility within the first 24 hours
after they were admitted to the intensive care unit (ICU) of Zhejiang
University Hospital between September 2012 and January 2019 (1, 45).
Information was extracted from a prospectively designed database.
A total of 524 patients who had CT of the abdomen within 2 months
prior to ICU admission or during ICU stay were enrolled. Exclusion
criteria were age younger than 18 years or older than 80 years, with
liver cirrhosis, with alcohol consumption (>140 g/week in men or >70
g/week in women), with a previous positive test for hepatitis B surface
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Figure 9. Increase in TREM2 gene dosage reduces steatohepatitis and sepsis-induced liver injury. (A) Experimental design used to evaluate the role of
elevated TREM2 gene dosage in NAFLD progression and sepsis. (B and C) Body weight (B) and liver weight (C) of BAC-TREM2 and littermate WT control
mice after a 10-week HFD. n = 11 in WT group; n = 15 in BAC-TREM2 group. Filled and open symbols refer to male and female, respectively. (D–F) Representative images of H&E-stained and ORO-stained liver sections (D). H&E revealed tissue composition, macrovesicular fat, hepatocyte ballooning, and
lobular inflammation. ORO visualized lipid droplets. Number of hepatocytes with macrovesicular fat or hepatocyte ballooning, lobular inflammation score,
and percentage of ORO-positive area per HMF was determined by ImageJ from 5 fields per section (E and F). n = 7 in WT group; n = 11 in BAC-TREM2 group.
Scale bar: 100 μm. (G and H) Levels of hepatic triglyceride (G) and ATP (H) from BAC-TREM2 and littermate WT mice after a 10-week HFD. n = 7 in WT
group; n = 11 in BAC-TREM2 group. (I and J) Organ injury and bacteria burden at 24 hours after CLP. Male BAC-TREM2 and WT mice were fed with HFD for
10 weeks. After dietary intervention, mild polymicrobial sepsis was induced by CLP (24-gauge needle). At 24 hours after CLP, livers, lungs, and blood were
collected for H&E staining (I) and bacterial burden test (J), respectively. n = 6 in WT group; n = 5 in BAC-TREM2 group. Scale bar: 100 μm. (K) Hepatic ATP
levels were quantified by luciferase assay. n = 6 in WT group; n = 5 in BAC-TREM2 group. Data are represented as the mean ± SD. Significance was determined by an unpaired, 2-tailed Student’s t test. *P < 0.05, **P < 0.01, ***P < 0.001.

antigen or hepatitis C antibody, and treatment with medications that
can cause hepatic steatosis. Based on the LA value ≤ 40 HU criteria
(hepatic steatosis area >30%, moderate-to-severe, refs. 16–19), 129
septic patients with NAFLD were identified. Clinical characteristics
of 524 adults with sepsis according to hepatic steatosis categories
are summarized in Supplemental Table 1. The study protocol was
approved by the local institutional review board, and written informed
consent was obtained from all subjects or their surrogates.

Liver tissues. Liver samples from NAFLD or apparently healthy
patients were obtained from donors who underwent organ donation after cardiac death (DCD) with proper ethical approvals from
institutional review boards. The exclusion criteria was the same
as mentioned above. The NAFLD activity was evaluated by biopsies at cold ischemia in all graft livers. The grade of liver steatosis
was determined according to international standards (46). Score
0 (non-NAFLD) indicates steatosis area < 5%; score 1–3 (NAFLD)
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Figure 10. Schematic illustration of a mechanism
through which macrophage TREM2 protects against
NAFLD associated sepsis. Under a free fatty acid–
enriched (FFA-enriched) environment, macrophage
TREM2 restrains the release of exosomes containing miR-106b-5p that targets to Mfn2 and leads to
mitochondrial fragmentation in liver cells. The severely
impaired energy supply in the Trem2–/– liver enhances
susceptibility to sepsis. Strategies that target macrophage TREM2 may be an effective way to suppress
steatohepatitis and relieve sepsis-induced liver dysfunction and multiple organ dysfunction syndrome.

indicates steatosis area ≥ 5%. All microscopic H&E-stained sections
and ORO-stained sections were evaluated by 2 pathologists in a double-blinded fashion. Nine non-NAFLD donors and 21 NAFLD donors
were included. NAFLD activity and liver function of the 30 donors
are summarized in Supplemental Table 2.
Mice. All animal experiments were reviewed and approved by
the Animal Advisory Committee at Zhejiang University and Washington University in St. Louis for the care and use of laboratory animals. Trem2-deficient (Trem2–/–) mice on C57BL/6 background or
BAC transgenic mice on C57BL/6 background and their littermate
WT controls were generated as previously described (12, 41). All the
mice were bred and maintained in a specific pathogen–free facility in
standard cages at 22°C to 24°C with a 12 hour light-dark cycle. Eightweek-old mice were fed a normal control diet (NCD) (18.3% protein,
10.2% fat, and 71.5% carbohydrates; Research Diets, D12450B) or
a high fat diet (HFD) (18.1% protein, 61.6% fat, and 20.3% carbohydrates; Research Diets, D12492) ad libitum for another 8 or 10
weeks. All fodder was replaced weekly to avoid contamination. For
characterization of liver under HFD or NCD conditions in different
genotype mice, all mice were fasted overnight prior to harvest.
RNA sequencing and differential expression analysis. Human/mouse
liver samples or isolated mouse KCs from mice fed HFD for 8 weeks
were subjected to parallel RNA sequencing using Illumina Hiseq platform (Novogene Experimental Department). Differential expression
analysis was performed using the DESeq2 R package (1.16.1) (47). Read
counts were used as input and normalized using built-in algorithms in
DESeq2. Pairwise comparisons among the 2 conditions/groups were
done on all genes. The resulting P values were adjusted using the Benjamini and Hochberg’s approach for controlling the false discovery
rate. Genes with an adjusted P value less than 0.05 found by DESeq2
were assigned as differentially expressed. GO enrichment analysis of
DEGs was implemented by the cluster Profiler R package, in which
gene length bias was corrected (48). GO terms with corrected P value
less than 0.05 were considered significantly enriched by DEGs.
MicroRNA sequencing (miRNA-seq) was profiled by the small
RNA sequencing analysis (Illumina). Using the KCs RNA-isolated
14

from WT or Trem2–/– mice fed HFD for 8 weeks, a small RNA library
was generated using the Illumina Truseq Small RNA Preparation kit
following the manufacturer’s guidelines. miRNA-seq reads were subjected to ACGT101-miR (LC Sciences) to sequence the data. Subsequently, unique sequences with length around 18–26 nucleotides were
then mapped to all mouse miRNA hairpin sequences in miRBase 22.0
to identify known miRNAs and novel 3p- and 5p-derived miRNAs
(49). Differential expression of miRNAs based on normalized deepsequencing counts was analyzed by selectively using a Student’s t test.
The significance threshold was set to 0.05 in each test. Sequencing data
supporting these studies can be found at the Gene Expression Omnibus
database under accession number GSE160022.
Kupffer cell depletion. Animals received 2 intravenous injections
of sterile GdCl3 (20 mg/kg; Millipore Sigma, G7532) or vehicle control per week during the HFD feeding. After 8 weeks of dietary exposure, animals were fasted overnight before the tissues (blood, liver,
adipose tissue) were harvested (32).
Cecal ligation and puncture model. Cecal ligation and puncture
(CLP) was performed as described previously (45, 50). Briefly, mice
were anesthetized with an i.p. injection of ketamine/xylazine (100
mg/kg and 10 mg/kg). After a 1.5 cm abdominal incision, the cecum
was externalized, ligated (75%) with 4:0 silk sutures, and punctured
once with an 18-gauge needle (lethal) or 24-gauge needle (mild/less
catastrophic) by one through-and-through puncture. We then internalized the cecum, closed the incision with 4:0 sutures, and resuscitated mice with 1 mL subcutaneous sterile saline. For survival experiments, mice were observed for mortality every 12 hours. In some
experiments, mice were sacrificed at 24 hours post-CLP surgery, and
then blood and organs were harvested.
Exosome purification and characterization. Exosomes were isolated by differential ultra-centrifugation as described previously (6, 33).
BMDMs with different genotype were stimulated with 0.5 mM PA
(Millipore Sigma, P0500) or control vehicle for 12 hours in exosome
free medium. Dead cells and debris in culture media (depleted from
serum-exosomes) were first removed by centrifuging at 350g for 5
minutes, and then the supernatant underwent a second centrifugation
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at 2000g for 20 minutes and a third centrifugation at 16,500g for 30
minutes. The supernatant was then subjected to ultracentrifugation at
110,000g for 2 hours. After washing with sterile PBS and being recentrifuged at 110,000g for 2 hours, the exosome-containing pellet was resuspended by PBS. Protein concentration was determined by bicinchoninic
acid assay (Thermo Fisher Scientific, 23227). Further, exosome size
distribution was measured by nanoparticle tracking analysis using
the NanoSight LM10 (Malvern Panalytical). The device measures the
Brownian motion of particles whose speed of motion, or diffusion coefficient, is related to particle size through the Stokes-Einstein equation.
Exosome in vivo treatment. Exosomes (30 μg) derived from PA-treated (0.5 mM, 12 hours) BMDMs were rapidly injected into WT mice via tail
vein with a volume of 200 μL. Exosomes were injected every week started at 7 weeks and mice were sacrificed at 10 weeks post-HFD feeding. To
monitor the exosome trafficking after tail vein injection, exosomes were
stained by lipophilic PKH26 fluorescent dye (Millipore Sigma, Mini261KT) before injection. Liver and visceral adipose tissue (VAT) sections
(10 μm) were observed by Nikon A1R confocal microscope.
Primary hepatocyte isolation and culture. Primary hepatocytes were
isolated from age-matched WT or Trem2–/– male mice using released
publications as reference (51). Briefly, mice were anesthetized by i.p.
injection of ketamine/xylazine (100 mg/kg and 10 mg/kg). Livers
were fully perfused through portal vein with liver perfusion buffer
and then digested with dispase (Gibco, 17105-041) and collagenase
type-I (Gibco, 17100-017) for 2 minutes at a rate of 2 mL/min. Then
liver was excised, minced, and filtered through a 200 μm mesh. Primary hepatocytes were washed by washing buffer containing 0.1 g/L
DNase (Sinopharm Chemical Reagent Co., Ltd, 64002860), 0.1 g/L
MgSO2·7 H2O and 0.1 g/L MgCl2·6 H2O and then separated via centrifugation at 110g for 2 minutes. Primary hepatocytes were cultured
in the DMEM supplemented with 10% FBS and 1% penicillin-streptomycin in a humidified incubator for 6 hours. The medium was then
removed and replaced with fresh HepatoZYME-SFM medium (Gibco,
17705-021) supplemented with 1% l-glutamine (Thermo Fisher Scientific, 25030081) and 1% penicillin-streptomycin for future study.
Cell treatment. mmu-miR-106b-5p mimic or NC were synthesized
by GenePharma (B02001 or B04003, respectively). In some experiments, miR-106b-5p was labeled with Cy3 before transfection. To
transfect miRNAs into BMDMs, lipofectamine RNAiMAX reagent
(Thermo Fisher Scientific, 13778150) was used to package miR-106b5p mimic or NC. The transfection efficiencies were validated by qPCR.
For hepatocyte-macrophage coculture experiments, primary hepatocytes were isolated as above and seeded in the bottom chamber of transwell culture system with 0.4 mm polycarbonate filter (1.5 × 105 per well;
Corning, 3413) and rested for 6 hours before use. Different genotype
BMDMs or WT BMDMs transfected with mimic miR-106b-5p or NC
were then seeded in the upper chamber (1.5 × 105 per well) and cocultured
with hepatocytes for 24 hours with 0.5 mM PA in the culture medium.
For exosome treatment experiments, primary hepatocytes isolated from WT mice were seeded in a 12-well plate (2.5 × 105 per well)
and treated by 20 μg/mL WT or Trem2–/– BMDM–derived exosomes
for 12 hours. To determine the Mfn2 expression of hepatocytes, BNL.
CL2 cells were placed in a 12-well plate (2.5 × 105 cells per well) and
then transfected with miR-106b-5p mimic or NC for 24 hours.
TEM. For mitochondrial ultrastructure, liver tissue was dissected
and fixed in 2.5% glutaraldehyde overnight at 4°C, post-fixed in 1%
osmium tetroxide for 80 minutes at 4°C, dehydrated through a graded

ethanol series, and embedded in epoxy resin. The tissue was sliced
using an ultra-microtome (Leica EM UC7). Ultrathin sections (100
nm) were mounted on copper grids and contrasted with 4% uranyl
acetate and lead citrate. For exosome characters, exosomes resuspended in PBS as described above were pipetted onto 200 μm mesh
formvar/carbon grids (EMS) which had been glow-discharged for 15
seconds. Samples were incubated on grids for 30 seconds and subsequently negatively stained with a 2% uranyl acetate solution. Grids
were observed with TEM (Tecnai G2 Spirit 120kV, Thermo Fisher
Scientific) at the Center of Cyro-Electron Microscopy, Zhejiang University. The images for hepatocyte and exosomes were taken independently. Quantification of mitochondrial parameters in hepatocytes
was performed using ImageJ (length, diameter, and area; ref. 52). The
percentage of damaged mitochondria was calculated. All quantifications were performed in double-bind fashion.
RNA isolation and detection of miRNA and mRNA. Total RNA was
isolated either from tissue samples or cultured cells using TRIzol
reagent (Thermo Fisher Scientific, 15596-026). The obtained total
RNA was then reverse-transcribed into cDNA using the Reverse
Transcription System (Promega, A3500) or the Mir-X miRNA firststrand synthesis kit (Takara, 638313) according to the manufacturer’s
instructions. TB Green premix Ex Taq II (Takara, RR820A) was used
to quantify the PCR amplification products. The mRNA expression
levels of the target genes were normalized to β-actin/GAPDH expression (Supplemental Table 3) and the miR-106b-5p expression levels
were normalized to U6 (GeneCopoeia; mmu-miR-106b-5p primer:
HmiRQP0029; U6 primer: HmiRQP9001). For exosome miRNA
samples, 5 pg cel-miR-39 mimic (Qiagen, 219610) was added as an
external control before isolated. The 2−ΔΔCt method was used to calculate relative gene expression levels.
Liver macrophage sorting and analysis. Liver macrophage sorting
was performed using BD FACS Aria II flow cytometer (BD Biosciences). In brief, livers from HFD-fed mice were digested with collagenase
type-I and DNase at 37°C after a low-pressure intraportal perfusion
with EDTA and dispose solution. Cell suspension was filtered through
Nylon gauze mesh, and centrifuged at 1000g for 10 minutes. Then,
single cells were isolated by using lymphocyte separation medium
(DAKEWE, 7211011). After washed by PBS, liver nonparenchymal cells
(NPCs) were stained by anti-mouse F4/80 (BM8, rat monoclonal, 1:50;
Thermo Fisher Scientific, 12-4801-82) and anti-mouse CD11b (M1/70,
rat monoclonal, 1:50; BD Biosciences, 553312) for 20 minutes while
protected from light. Monocyte-derived macrophages (F4/80+CD11bhi) and KCs (F4/80hiCD11b+) were acquired on the sorting flow
cytometer and analyzed using FlowJo version 10 software (Tree Star).
Statistics. All data are presented as mean ± SD. Calculation for
statistical significance was measured using 2-tailed Student’s t test
or 1-way analysis of variance with Bonferroni corrections or Fisher’s
exact test as indicated in figure legends. Survival rates were analyzed
using the log-rank test. Logistic regression analysis was used to examine covariate-adjusted associations between NAFLD and hospital
mortality. Numbers of cohorts and n values for each experiment are
indicated in figure legends. All statistical analyses were performed
using Prism 8.0 software (GraphPad Software Inc.), and P values less
than 0.05 were considered statistically significant.
Study approval. Human study protocols were approved by the institutional review board of Zhejiang University and written informed consent was obtained from all subjects or their surrogates. All animals were
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housed and procedures performed under a protocol approved either
by the Animal Advisory Committee at Zhejiang University (protocol
2017-442) or Washington University in St. Louis (protocol 19-0981).
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